About us

Our history Our team Our partners

Founded in 2009, Fabentech specialises in the development and production of polyclonal antibody treatments for fighting high-priority biological agents which could threaten public health.

Our platform is based on a safe, tested and fully validated polyclonal antibody technology, initially developed by Sanofi Pasteur and enhanced by the Fabentech R&D team for more than a decade. Our Integrated R&D and proprietary manufacturing site enable rapid developments of medical countermeasures against different targets. We are using our expertise to offer reliable protection and treatments ready to face proliferating risks.

Our history

Fabentech has over 14 years of experience in the development and production of emergency care solutions and medical countermeasures.

Fabentech’s key milestones


Inception of the company


Phase I Clinical study of FabenFLU® treatment against H5N1 Avian Influenza infection.


Launch of the Ebola Program in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).

Orphan drug status (ODD) in Europe for FabenFLU® treatment against H5N1 Avian Influenza infection.


First collaboration with the French Army on a first antidote against a highly lethal plant-based toxin.


Fabentech raises 8.5 million euros led by Definvest, the Armed forces ministry fund managed by Bpifrance, with participation by Institut Mérieux and its historical investors.


Launch of FabenCOV®, an immunotherapy program to treat Covid-19 infections

Sebastien IVA is appointed CEO of Fabentech

Bio-production: Fabentech presents its new industrial site


Fabentech is awarded 9.2 million euros to develop its FabenCOV® treatment against Covid-19 and its variants in the context of European HERA projects


Launch of a new program to treat Nipah virus infection

The company is granted of 5m€ through the COUNTERACT European consortium to launch several biodefence programs funded by the European Defense Fund.


Launch of e-FabRIC, a European Consortium coordinated by Fabentech, to develop a new treatment in order to combat future epidemic outbreaks caused by Sarbecoviruses, a highly pathogenic viral family.

Launch and first results of first-in-human clinical trial evaluating the safety of its antidote against a deadly plant-based toxin of bioterrorism interest.

Our team

Fabentech can count on the skills and energy of an experienced and mobilised team with strong track records in the pharmaceutical industry.

Executive committee

Management team

Supervisory board

  • Philippe Archinard
    Chairman of the supervisory board, Institut Mérieux
  • Franck Lescure
    Auriga Partners, a venture capital management firm
  • Guillaume Hemmerle
    Trail, a venture capital management firm
  • Marielle Mailhes
    BPI France Investissement, Public Bank of Investment
  • Sandra Dubos
    Kreaxi, an investment management firm, specialised in equity financing of innovative startups
  • Bertrand Lépine
    Founder of Fabentech
  • Albert Saporta

Fabentech successful team


Our partners

From public support to research institutes, Fabentech can count on a network of local, national and international partners to participate in the development of its medical countermeasures.


Public supports

Research Institutes


Download Fabentech presentation